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Defining Inflammatory Cell States in Rheumatoid Arthritis Joint Synovial Tissues by 
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To define the cell populations in rheumatoid arthritis (RA) driving joint inflammation, we applied 
single-cell RNA-seq (scRNA-seq), mass cytometry, bulk RNA-seq, and flow cytometry to sorted 
T cells, B cells, monocytes, and fibroblasts from 51 synovial tissue RA and osteoarthritis (OA) 
patient samples. Utilizing an integrated computational strategy based on canonical correlation 
analysis to 5,265 scRNA-seq profiles, we identified 18 unique cell populations. Combining mass 
cytometry and transcriptomics together revealed cell states expanded in RA synovia: 
THY1+HLAhigh sublining fibroblasts (OR=33.8), IL1B+  pro-inflammatory monocytes (OR=7.8), 
CD11c+T-bet+ autoimmune-associated B cells (OR=5.7), and PD-1+ Tph/Tfh (OR=3.0). We also 
defined CD8+ T cell subsets characterized by GZMK+, GZMB+, and GNLY+ expression. Using 
bulk and single-cell data, we mapped inflammatory mediators to source cell populations, for 
example attributing IL6 production to THY1+HLAhigh fibroblasts and naïve B cells, and IL1B to 











Rheumatoid arthritis (RA) is an autoimmune disease affecting up to 1% of the population where 
a complex interplay between many different cell types drives chronic inflammation in the 
synovium of the joint tissue1–3. This inflammation leads to joint destruction, disability and 
shortened life span4. Defining key cellular subsets and their activation states in RA has been a 
longstanding key step to defining new therapeutic targets. CD4+ T cell subsets5,6, B cells7, 
monocytes8,9, and fibroblasts10–12 have established relevance to RA pathogenesis.  A global 
portrait of RA-relevant cell subsets using single cell technologies across a large sample 
collection tissues from inflamed joints is a critical resource for advancing therapeutics. 
Application of transcriptomic and cellular profiling technologies to whole synovial tissue has 
already identified promising specific cellular populations associated with RA3,13–15. However, 
most studies have focused on a pre-selected cell type, surveyed whole tissues rather than 
disaggregated cells, or used only one technology. Latest advances in single-cell technologies 
offer an opportunity to identify disease-associated cell subsets in human tissues at high 
resolution in an unbiased fashion16–19. These technologies have already indicated roles for T 
peripheral helper (Tph) cells20 and HLA-DR+CD27– cytotoxic T cells21 in RA pathogenesis. 
Separately, scRNA-seq has defined myeloid cell heterogeneity in human blood22 and identified 
a distinct subset of PDPN+CD34–THY1+ (THY1, also known as CD90) fibroblasts enriched in RA 
synovial tissue16,23.   
To generate high-dimensional multi-modal single-cell data from synovial tissue samples, 
we developed a robust tissue analytical pipeline24 in the Accelerating Medicines Partnership 
(AMP) RA/SLE consortium. We collected and disaggregated tissue samples from patients with 
RA and OA, and then subjected constituent cells to scRNA-seq, sorted-population bulk RNA-
seq, mass cytometry, and flow cytometry. We developed a robust computational strategy based 
on canonical correlation analysis (CCA) to integrate multi-modal transcriptomic and proteomic 
profiles at a single cell level. A unified analysis of single cells across data modalities can 




Generation of parallel mass cytometric and transcriptomic data from synovial tissue  
In phase 1 of AMP-RA/SLE, we recruited 36 RA patients meeting 1987 ACR classification 
criteria and 15 OA control patients from 10 clinical sites over 16 months (Supplemental Table 
1) and obtained synovial tissues from ultrasound guided synovial biopsies or joint replacements 
(Methods). All tissue samples included had with synovial lining documented by histology (Fig. 
1a). Synovial tissue disaggregation yielded many viable cells (362,190 cells per tissue, S.E.M 
7,687 cells) for downstream analyses. Applying a previously validated strategy for synovial cell 
sorting24 (Fig. 1a), we separated cells into B cells (CD45+CD3–CD19+), T cells (CD45+CD3+), 
monocytes (CD45+CD14+), and stromal fibroblasts (CD45–PDPN+) (Supplemental Fig. 1a). We 
applied bulk RNA-seq to all four sorted subsets from the 51 samples. For a subset of samples 
with sufficient cell yield (Methods), we measured single-cell protein expression using a 34-
marker mass cytometry panel (n=26, Supplemental Table 2), and single-cell RNA expression 
in sorted populations (n=21, Fig. 1b). 
  
Summary of computational data integration strategy to define cell populations 
To confidently define RA associated cell populations, high overlap between different assays on 
each individual patient sample allows us to integrate multiple data types from the same patient 
(Fig. 1b-c). We use bulk RNA-seq data as the reference point because the bulk RNA-seq data 
were available for almost all of the samples, had the highest dimensionality and least sparsity, 
and were the least sensitive to technical artifacts (Fig. 1b). 
We used CCA to integrate bulk RNA-seq data with the three other datasets (Fig. 1c). 
Integrating scRNA-seq with bulk RNA-seq data ensures robust discovery of individual cellular 
populations. Here, we used CCA to find linear combinations of bulk RNA-seq samples and 
scRNA-seq cells (Fig. 1d) to create gene expression profiles that were maximally correlated. 
These linear combinations captured sources of shared variation between the two datasets and 
allowed us to identify individual cellular populations that drive variation in the bulk RNA-seq 
data. We clustered scRNA-seq data by using the most correlated canonical variates for each 
cell to compute a nearest neighbor network, and then identified clusters with a community 
detection algorithm (Methods, Supplemental Fig. 2). 
We identified clusters of cells in mass cytometry data using density-based clustering25. 
To define the genes that best correspond to the mass cytometry clusters, we integrated bulk 
RNA-seq with mass cytometry using CCA. In this analysis, CCA identifies linear combinations of 
genes and mass cytometry cluster proportions so that correlation across individual samples is 
maximized. These canonical variates offer a way to visualize genes and mass cytometry 
clusters together and define genes possibly specific for individual clusters. We then integrated 
mass cytometry clusters with identified scRNA-seq clusters to define the relationship between 
them (Methods). We also associated bulk gene expression in each sample with proportions of 
cells in different flow cytometry gate by integrating bulk RNA-seq with flow cytometry data using 
CCA. 
  
Disease association test of cellular populations 
We tested whether abundances of individual populations were altered in RA case samples 
compared to controls using two ways. First, we assessed whether marker genes (AUC > 0.7, 20 
< n < 100) of each scRNA-seq derived cluster was differentially expressed concordantly in bulk 
RNA-seq samples. Second, we applied MASC26, a single cell association testing framework, to 
identify mass cytometry clusters associated with disease (Methods). 
 
Flow cytometry features define a set of RA synovia that are leukocyte-rich 
Histology of RA synovial tissues revealed heterogeneous tissue composition with variable 
lymphocyte and monocyte infiltration (Fig. 2a,b); in contrast OA tissues had minimal 
lymphocytic infiltration (Fig. 2a). This expected heterogeneity reflects variable disease activity 
among RA patients which results in differences in tissue immune cell infiltration27. 
Consequently, we employed a data-driven approach to separate samples based on the degrees 
of lymphocyte and monocyte infiltration of tissues measured by flow cytometry (Supplemental 
Fig. 1b,c). We calculated a multivariate normal distribution of these parameters based on OA 
samples as a reference, and then for each RA sample calculated the Mahalanobis distance 
from OA28. We defined the maximum OA value (4.5) as a threshold to separate all leukocyte-
rich RA samples from leukocyte-poor samples (Methods, Supplemental Fig. 1d). We defined 
19 leukocyte-rich RA and 17 leukocyte-poor RA samples in our cohort. Whereas leukocyte-rich 
RA tissues had marked infiltration of synovial T cells and B cells (Fig. 2c), leukocyte-poor RA 
tissues had a similar cellular composition of leukocytes and stromal fibroblasts as OA (Fig. 2c). 
Synovial monocytes were similar between RA and OA (Fig. 2c). 
Mass cytometry in 26 synovial tissues was consistent with flow cytometric and histologic 
analyses. We observed marked differences in synovial cellular composition between leukocyte-
rich RA, leukocyte-poor RA, and OA. Stromal fibroblasts and endothelial cells constituted most 
synovial cells in OA and leukocyte-poor RA and are otherwise characterized by expansion of 
monocytes with few lymphocytes (Fig. 2f, Supplemental Fig. 3). In stark contrast, leukocyte-
rich RA tissues constituted predominantly of CD4 T, CD8 T, and B cells (Fig. 2f). To validate 
whether our classification indicated inflammation, we assessed tissue histology and assigned a 
Krenn inflammation score29. We observed that leukocyte-rich RA samples exhibited significantly 
higher score than leukocyte-poor RA and OA (Fig. 2d). In contrast, synovial lining membrane 
hyperplasia was not significantly different between leukocyte-rich RA, leukocyte-poor RA, and 
OA controls. We observed significant correlation between synovial leukocyte infiltration and 
histologic inflammation score (t-test p=5e-04; Spearman’s rho = 0.55, Fig. 2e), suggesting 
consistent classification between cytometric and histologic assessments. 
  
Single-cell RNA-seq analysis reveals distinct cell subpopulations 
Next, we analyzed 5,265 scRNA-seq profiles passing stringent quality control, including 1,142 B 
cells, 1,844 fibroblasts, 750 monocytes, and 1,529 T cells (Methods). We used canonical 
variates (from bulk RNA-seq integration) to define 18 clusters that were independent of donor 
and sequencing batch effects (Fig. 3a-b, Supplemental Fig. 4a). Protein fluorescence 
measurements by flow cytometry of typical cell type markers on each single cell agree with our 
identified scRNA-seq cell type clusters (Supplemental Fig. 5b). In contrast, conventional PCA-
based clustering led to clusters that were confounded by batch effects (Supplemental Fig. 4b). 
After removing clusters that are clearly confounded by batch effects, we observed that there 
were no other missed cell type clusters that were not identified in our single-cell RNA-seq 
analyses. We selected marker genes for scRNA-seq clusters by comparing cells within it to cells 
outside it and applied the following criteria: 1) percent of non-zero expressing cells > 60%; 2) 
AUC score > 0.7; and 3) FC > 2 (Supplemental Table 4). CCA-based clustering identified 18 
clusters (4 fibroblast clusters, 4 monocyte clusters, 6 T cell clusters, and 4 B cell clusters) from 
21 donors (Fig. 3a, interactive form both at the cellBrowser: 
https://immunogenomics.io/cellbrowser/ and the Broad Institute Single Cell Portal: 
https://portals.broadinstitute.org/single_cell/study/amp-phase-1). The distribution of these 
distinct clusters varies between donors, suggesting heterogeneity in immune and stromal cell 
subsets across patients (Fig. 3b, Supplemental Fig. 5a). We show typical markers for cells in a 
t-Distributed Stochastic Neighbor Embedding (tSNE30) into two-dimensional space (Fig. 3c-f). 
Here we briefly summarize these populations. 
Within stromal fibroblasts, we identified four putative cell subpopulations (Fig. 3c). The 
CD55+ (SC-F4) cluster represented lining fibroblasts and were the most different from the other 
fibroblast clusters16,23. The other three fibroblast clusters were CD34+ sublining fibroblasts (SC-
F1), HLAhigh sublining fibroblasts (SC-F2), and DKK3+ sublining fibroblasts (SC-F3). In 
monocytes (Fig. 3d), we identified IL1B+ pro-inflammatory monocytes (SC-M1), NUPR1+ 
monocytes (SC-M2), C1QA+ monocytes (SC-M3), and IFN-activated monocytes (SC-M4). In T 
cells (Fig. 3e), we identified three CD4+ clusters: CCR7+CD4+ T cells (SC-T1), FOXP3+ Tregs 
(SC-T2), and PD-1+ Tph/Tfh (SC-T3). We also found three CD8+ clusters: GZMK+ T cells (SC-
T4), GNLY+GZMB+ cytotoxic lymphocytes (CTLs) (SC-T5), and GZMK+/GZMB+ T cells (SC-T6). 
Within B cells (Fig. 3f), we identified four cell clusters, including naive IGHD+CD27– (SC-B1) 
and IGHG3+CD27– memory B cells (SC-B2). Intriguingly, we identified an autoimmune-
associated B cell (ABC) cluster (SC-B3) with high expression of ITGAX (CD11c)31,32. We also 
identified a plasmablast cluster (SC-B4) with high expression of IgG genes and XBP1, a 
transcription factor critical for plasma cell differentiation33. 
  
Distinct synovial fibroblasts defined by cytokine activation and MHC II expression 
In synovial fibroblasts, differential single cell gene expression suggested that CD55+ fibroblasts 
(SC-F4) were the most transcriptionally distinct subset from the three sublining THY1+ clusters 
SC-F1, SC-F2, and SC-F3, indicating that anatomical localization contributes to synovial 
fibroblast diversity16,23 (Fig. 4a). To identify fibroblast populations expanded in leukocyte-rich RA 
synovia, we first examined expression of genes associated with each fibroblast subsets from 
bulk-sorted fibroblasts (CD45–PDPN+) from RA and OA patients. Expression of genes 
associated with HLAhigh fibroblasts (HLA-DRA, IFI30, and IL6, t-test p<1e-3) were upregulated in 
leukocyte-rich RA (n=16) compared to OA (n=12) by bulk RNA-seq (Fig. 4a), suggesting 
expansion of SC-F2. Genes associated with SC-F4 lining fibroblasts (HBEGF, CLIC5, HTRA4, 
and DNASE1L3, t-test p<1e-3) were significantly decreased in leukocyte-rich RA (Fig. 4a). 
Next, we used the most differentially expressed genes (AUC>0.7) in each fibroblast subset to 
query transcriptomic profiles of bulk-sorted fibroblasts from leukocyte-rich RA and OA synovia. 
HLAhigh sublining fibroblasts (SC-F2) and CD34+ sublining fibroblasts (SC-F1) were significantly 
expanded in RA synovia compared to OA (t-test p=2.5e-6 and p=2.1e-3, respectively), while 
CD55+ lining fibroblasts (SC-F4) were relatively decreased in leukocyte-rich RA (t-test p=5.0e-7) 
(Fig. 4b). 
Consistent with the role of synovial fibroblasts in matrix remodeling, the three sublining 
fibroblasts, CD34+ fibroblasts (SC-F1), HLAhigh fibroblasts (SC-F2), and DKK3+ fibroblasts (SC-
F3) share gene expression in pathways related to extracellular matrix constituents by gene set 
enrichment analysis (GSEA) (Fig. 4c). HLAhigh sublining fibroblasts (SC-F2) are enriched with 
genes related to MHC class II presentation (HLA-DRA and HLA-DRB1) and the interferon 
gamma-mediated signaling pathway (IFI30) (Fig. 4a,c), suggesting upregulation of MHC class II 
in response to interferon-gamma signaling in these cells. We identified a novel sublining 
fibroblast subtype (SC-F3) that is characterized by high expression of DKK3, CADM1 and 
COL8A2 (Fig. 4a). 
We then queried the proteomic expression to validate these four fibroblast populations. 
Analysis of CD45–PDPN+ cells identified eight putative cell clusters based on the differential 
expression pattern of THY1, HLA-DR, CD34, and Cadherin11 (Fig. 4d-g) that were not 
confounded by obvious batch effects (Supplemental Fig. 6a). Integration of mass cytometry 
clusters with bulk RNA-seq using CCA showed that the IL6, CXCL12, and HLA gene expression 
is highly associated with frequency of THY1+CD34–HLA-DRhigh fibroblasts, suggesting an active 
cytokine-producing state (Fig. 4h). In contrast, the expression of lining fibroblast genes PRG4 
and CD55 separated in the CCA space with a gradient, indicating relative decreased number of 
lining fibroblasts in leukocyte-rich synovium (Fig. 4h). We then integrated each scRNA-seq 
subset based on the most unique genes (AUC>0.7) with the identified mass cytometry clusters 
and determined the statistical significance (z-score) of this association by explicit permutation 
(Fig. 4i, Methods). We consistently observed that HLAhigh sublining fibroblasts (SC-F2) are 
strongly associated (z-score=2.8) with THY1+CD34–HLA-DRhigh fibroblasts, and CD34+ sublining 
fibroblasts (SC-F1) are strongly correlated (z-score=2.7) with THY1+CD34+HLA-DRlow fibroblasts 
(Table 1) indicating that these populations correspond to each other. Consistent with the 
differential expression analyses, we found that THY1+CD34–HLA-DRhigh cells are dramatically 
overabundant in leukocyte-rich RA compared to leukocyte-poor RA and OA controls (36% 
versus 2% of fibroblasts, MASC OR = 33.8 (95% CI: 11.7-113.1), one tailed MASC p=1.9e-05) 
(Table 1).  
In a validation experiment, we sorted cells with predicted marker and subjected to bulk 
RNA-seq (Supplemental Fig. 17a). We observed the sorted THY1- DR- population are 
predicted to be the same with SC-F4 (THY1-) single cells and THY1+ DR+ population also 
match with the cluster SC-F2 (THY1+ HLAhigh) cells (Supplemental Fig. 18a-d). The identified 
putative single-cell cluster markers are strongly differentially expressed in bulk THY1+ DR+ and 
THY1- DR- populations. 
  
Unique activation states define heterogeneity among synovial monocytes 
With scRNA-seq, we defined four transcriptionally distinct monocyte subsets: IL1B+ pro-
inflammatory monocytes (SC-M1), NUPR1+ monocytes (SC-M2), C1QA+ monocytes (SC-M3) 
and IFN-activated monocytes (SC-M4) (Fig. 5a). By querying bulk RNA-seq monocyte samples 
from leukocyte-rich RA (n=17) and OA samples (n=13), we found that genes associated with 
IL1B+ monocytes (SC-M1), including NR4A2 (t-test p=2.2e-05), HBEGF (t-test p=1.2e-4), 
PLAUR (t-test p=1.5e-4) and the IFN-activated monocytes gene IFITM3 (t-test p=9.3e-05) were 
significantly upregulated in leukocyte-rich RA samples. In contrast, marker genes associated 
with NUPR1+ monocytes (SC-M2) were relatively depleted in leukocyte-rich RA (Fig. 5a). 
Extensive examination of the top differentially expressed genes (AUC>0.7) for each monocyte 
subset confirmed a significant enrichment of IL1B+ monocytes (t-test p=6.1e-5) and IFN-
activated monocytes (t-test p=6.2e-3) in leukocyte-rich RA synovia in contrast to a relative 
depletion of NUPR1+ monocytes (t-test p=2.2e-5) (Fig. 5b). These data indicate that cytokine 
activation drives the expansion of unique monocyte populations in active RA synovia. 
 GSEA analysis demonstrated that monocyte LPS response was associated with SC-M1 
(44.8% of total monocytes) (Fig. 5b), suggesting it represents a phenotype similar to IL-1- or 
TLR-activated proinflammatory monocytes. Using Gene Ontology gene sets, we observed that 
SC-M4 monocytes were highly enriched in the type I interferon signaling and the interferon-
gamma mediated pathway (Supplemental Fig. 7a), including increased expression of IFITM322 
and IFI6 (Fig. 5a). The phenotypes of the monocytes from SC-M2 and SC-M3 clusters do not 
align well with known activation states, possibly indicating a more homeostatic role in the 
synovium. 
Supporting the idea that RA synovium is characterized by an exacerbated pro-
inflammatory response, we also use immunofluorescence staining to validate SC-M1 (IL1B+ pro-
inflammatory monocytes) and saw a massive recruitment of CD14+ cells, and clearly we were 
able detect CD14+IL1B cells (Fig. 5d).  
Mass cytometry identified five synovial CD14+ monocyte clusters (CD45+CD3–) (Fig. 5e-
h) without obvious batch effects (Supplemental Fig. 6b). A CCA-based integration of mass 
cytometry and bulk RNA-seq data indicated that monocyte genes enriched in RA subsets, such 
as IFITM3, PLAUR, CD38, and HLA genes, are associated with CD11c+CCR2+ and 
CD11c+CD38+ mass cytometry clusters (Fig. 5i). These markers may define inflammatory 
synovial monocyte populations. We further associated proteomic expression of monocytes with 
distinct scRNA-seq clusters based on marker genes (AUC>0.7) and observed that population 
defined by cell surface CD11c+CD38+ is highly associated with the activated monocytes states 
(SC-M1 and SC-M4) (z-score=2.3) (Fig. 5j, Table 1). To validate this, we sorted synovial 
monocytes using markers CD14, CD11c, and CD38 and isolated for bulk RNA-seq 
(Supplemental Fig. 17c). We observed the sorted CD14+CD11c+++CD38+++ and 
CD14+CD11c+CD38- populations are predicted to be the same with SC-M1 (IL1B+ pro-
inflammatory) and SC-M2 (NUPR1+) cells (Supplemental Fig. 18e-g). The marker genes from 
single-cell cluster SC-M1 and SC-M2 are strongly differentially expressed in these two bulk 
populations as well (Supplemental Fig. 18h). 
Supporting this finding, indeed using MASC, we confirmed that synovial CD11c+CD38+ 
monocytes are significantly expanded in leukocyte-rich RA (OR = 7.8 (95% CI: 3.6-17.2), one 
tailed MASC p=6.7e-05) (Table 1). Conversely, monocytes from cluster SC-M2 correlate with 
CD11c– by mass cytometry and are inversely correlated with inflammatory monocyte 
populations (z-score=2.7) (Fig. 5j, Table 1). 
  
Heterogeneity in synovial CD4 and CD8 T cells defined by effector functions 
Single-cell RNA-seq data defined distinct CD4+ and CD8+ T cell populations (Fig. 6a). Among 
CD4+ T cells, expression of CCR7 and SELL were notably higher in SC-T1 and the central 
memory T cells gene set is enriched in SC-T1 expressed genes (Fig. 6a), supporting the 
identification of SC-T1 as central memory T cells. Next, we identified two populations of CD4+ T 
cells marked by high expression of FOXP3 (SC-T2) and CXCL13 (SC-T3). Examination of 
differentially expressed genes between these two T cell subsets suggested that SC-T2 
represents FOXP3+ Tregs34 while SC-T3 represents PD-1+ Tph cells and Tfh cells20 
(Supplemental Fig. 8). Chemokine CXCL13 in Tph cells (SC-T3) in bulk-sorted T cells were 
upregulated in leukocyte-rich RA synovia comparing to OA by bulk-sorted T cells (CD45+CD14–
CD3+), including (t-test p=1.2e-4) (Fig. 6a). This likely reflected expansion of Tph cells and 
activated T cell subsets. Indeed, unbiased interrogation of bulk RNA-seq T cell data using the 
top differentially expressed genes (AUC>0.7) among scRNA-seq T cell subsets revealed 
significant expansion of Tph/Tfh cells (t-test p=0.01) (Fig. 6b). 
Single-cell RNA-seq analysis of synovial CD8+ T cells identified three unexpected 
populations characterized by distinct expression of effector molecules GZMK, GZMB, GZMA 
and GNLY (Fig. 6a). We defined these populations as GZMK+CD8+ (SC-T4), GNLY+GZMB+ 
cytotoxic T lymphocytes (CTLs) (SC-T5), and GZMK+/GZMB+ T cells (SC-T6). GZMK+/GZMB+ T 
cells not only expressed HLA-DRA and HLA-DQA1 at high levels, but also expressed genes 
suggestive of an effector phenotype (Fig. 6a,c). Using immunofluorescence staining, we 
observed that IFNg+CD3+CD8+ T cells were numerous in RA synovium (Fig. 6d). Inflamed RA 
synovial tissue also contained IFNg+CD3+CD8+ that presumably can be Th1 cells, and one or 
two IFNg+CD3-CD8- cells.  
Furthermore, we performed intracellular GzmK and GzmB staining on disaggregated 
synovial tissue samples from patients with RA (Supplemental Fig. 16a). At the protein level, 
the majority of CD8 T cells in synovial tissue express GzmK (Supplemental Fig. 16a). GzmK vs 
GzmB expression patterns vary from sample to sample, which is consistent with the variation 
across samples on the single-cell T cell clusters (Fig. 3b); HLA-DR+ CD8 T cells are 
preferentially found among CD8 T cells that express both GzmB and GzmK (Supplemental Fig. 
16b); CD8 T cells make IFN𝛾 at a higher frequency than CD4 T cells from the same synovial 
tissue sample (Supplemental Fig. 16c, d). Overall, these findings closely mirror the single-cell 
transcriptomic clusters. 
Using mass cytometry, we identified nine putative T cell clusters among the synovial T 
cells (CD45+CD14–CD3+) (Fig. 6e-h, Supplemental Fig. 6c). By integrating bulk RNA-seq with 
mass cytometry cluster abundances, we found that the gene expression of CXCL13 and 
inhibitory receptors TIGIT and CTLA4 are associated with abundance of the CD4+PD-1+ICOS+ 
mass cytometry cluster; the abundance of CD8+HLA-DR+ cells was associated with the 
expression of gene IFNG and HLA-DQA2 (Fig. 6i). When aggregating the differentially 
expressed marker genes (AUC>0.7) for scRNA-seq clusters, we consistently observed 
significant associations between Tph/Tfh cells (SC-T3) and CD4+PD-1+ICOS+ T cells (z-score = 
3.4); CD8+ subsets including GZMK+/GZMB+ (SC-T6), CTLs (SC-T5), and GZMK+ (SC-T4) and 
CD8+PD-1–HLA-DR+ T cells by mass cytometry (Fig. 6j, Table 1), confirming their respective 
identities. In addition, CD4+PD-1+ICOS+ cells were significantly expanded in leukocyte-rich RA 
(MASC OR = 3 (95% CI: 1.7-5.2), one tailed MASC p=2.7e-04) (Table 1). Interestingly, Tregs 
(SC-T2) exhibited nominal association with CD4+PD-1+ICOS+ and CD8+PD1+HLA-DR+ T cells 
(z-score = 1.5), potentially due to shared gene expression programs between Tregs, Tph/Tfh, 
and CD8+PD-1+HLA-DR+ T cells. 
  
Autoimmune-associated B cells expanded in RA synovium by single-cell RNA-seq 
We identified synovial B cell 4 clusters with scRNA-seq: naïve B cells (SC-B1), memory B cells 
(SC-B2), CD11c+ ABC cells (SC-B3), and plasmablasts (SC-B4) (Fig. 7a). Using Gene 
Ontology pathway enrichment for these four subsets we observed that MHC Class II protein 
complex and interferon-gamma-mediated signaling pathways were enriched in all the HLA+ 
subsets, SC-B1, SC-B2, and SC-B3 (Supplemental Fig. 7b), suggesting B cell activation. 
Pathway analysis on curated immunological genes sets demonstrated that SC-B1 expresses 
naïve B cell genes, while SC-B2 and SC-B3 are more enriched for IgM and IgG memory B cell 
genes (Fig. 7b). Intriguingly, we observed that SC-B3 cells express high levels of CD11c and T-
bet (Fig. 7b), which are autoimmune-associated B cells (ABC) markers31,32, as well as markers 
of recently activated B cells including ACTB35. High expression of AICDA is also in accord with 
the recently reported transcriptomic analysis of CD11c+ B cells from SLE peripheral blood36. 
Interferon stimulated genes (GBP1 and ISG15) are also expressed in the ABCs cluster (Fig. 
7a). While ABCs constitute as a relatively small proportion of all B cells, they are almost 
exclusively derived from two leukocyte-rich RA patients. Examination of bulk transcriptomic 
profiles of synovial B cell samples shows that genes GBP1, ITGAX (CD11c) genes are 
upregulated in leukocyte-rich RA (n=16) compared to OA (n=7) (Fig. 7a). 
Using immunofluorescence, we observed an increased number of CD20+ T-bet+ 
CD11C+ B cells (Fig. 7c). These cells were identified in tissue sections from the same inflamed 
synovial tissue that contained high proportion of ABCs by single cell analysis. Furthermore, we 
confirmed the flow sorted CD19+CD11c+ population is a validation for SC-B3 (ABCs) 
(Supplemental Fig. 17b, 18i-k). In this validation experiment, we found more putative marker 
genes (e.g. ZEB2 and CIITA) for the ABCs population, which show similar expression level with 
ITGAX (CD11c) and interferons (IFITM3 and IFI27). These genes could provide more insights 
into the functional role of the ABCs population (Supplemental Fig. l).  
     Mass cytometric data of synovial B cells (CD45+CD3–CD14–CD19+) identified ten 
putative B cell clusters (Fig. 7d-g, Supplemental Fig. 6d). Next, we analyzed bulk RNA-seq 
and mass cytometry cluster abundances from the shared samples, and found that the gene 
expressions of CD38, MZB1, and plasma cell differentiation factor XBP1 are associated with 
abundance of CD38++CD20–IgM–IgD– plasmablasts (Fig. 7h). To further validate the distinct 
scRNA-seq clusters using mass cytometry, we integrated ten mass cytometry populations with 
scRNA-seq clusters and observed significant correlation between plasmablasts (SC-B4) and 
CD38++CD20–IgM–IgD– B cells (z-score=2.7) (Fig. 7i, Table 1). Consistent with identification of 
ABCs in RA synovia, CD11c+ ABCs (SC-B3) were positively correlated (z-score=1.6) with IgM– 
IgD– HLA-DR++ CD20+ CD11c+, which is significantly (OR = 5.7 (95% CI: 1.8-22.3), one tailed 
MASC p=2.7e-03) expanded in leukocyte-rich RA (Fig. 7i, Table 1). Mass cytometry analysis 
further identified three putative subsets within CD11c+ cells based on expression of 
immunoglobulin profiles: IgM– IgD– HLA-DR++ CD20+ CD11c+, CD38+ HLA-DR++ CD20–  CD11c+, 
and IgM+ IgD+ CD11c, suggesting additional heterogeneity within ABCs. Among these, IgM+ IgD+ 
CD11c B cells express FcRL4, suggesting homology to a population of CD11c+FcRL4+ 
memory B cells described in the human tonsil. 
 
Inflammatory pathways and effector modules revealed by global transcriptomic profiling 
We used bulk and single cell transcriptomes of sorted synovial cells to detect pathogenic 
molecular signal pathways. First, principal component analysis (PCA) on post-QC OA and 
leukocyte-rich RA samples (Supplemental Fig. 9a,b) demonstrated that cell type accounted for 
most of the variance and each cell type expressed specific marker genes, PDGFRA for 
fibroblasts, C1QA for monocytes, CD3D for T cells, and CD19 for B cells (Supplemental Fig. 
9c). Within each cell-type we observed that leukocyte-rich RA appeared distinct from OA 
samples, but leukocyte-poor RA grouped together with OA samples (Supplemental Fig. 9d-g). 
We observed that 173 genes in fibroblasts, 159 genes in monocytes, 10 genes in T cells, and 5 
genes in B cells were upregulated in leukocyte-rich RA tissues compared to OA (FC>2 and 
FDR<0.01). To define the pathways relevant to leukocyte-rich RA, we applied GSEA weighted 
by gene effect sizes and identified TLR signaling (monocytes and B cells), type I interferon 
response and inflammatory response (monocytes and fibroblasts) (Supplemental Fig. 9h-i), Fc 
receptor signaling (monocytes), NF-kappa B signaling (fibroblasts), and interferon gamma (T 
cells) pathways (Fig. 8a). We observed that in fibroblasts and monocytes that inflammatory 
response genes (PTGS2, PTGER3, and ICAM1), interferon response genes (IFIT2, RSAD2, 
STAT1, and XAF1), and chemokine/cytokine genes (CCL2 and CXCL9) were significantly 
upregulated in leukocyte-rich RA (Fig. 8b), suggesting a coordinated chemotactic response to 
interferon activation. We also observed upregulation of interferon regulatory factors (IRFs), 
including IRF7 and IRF9 in T cells, and IRF1, IRF7, IRF8 and IRF9 in monocytes. Synovial 
monocytes in leukocyte-rich RA exhibit increased expression of TLR8 and MYD88, consistent 
with IL-1 or TLR signaling (Fig. 8a). Taken together, pathway analysis suggests crosstalk 
between immune and stromal cells in leukocyte-rich RA synovia. Inflammatory response genes 
upregulated in leukocyte-rich RA, had comparable expression in leukocyte-poor RA and OA 
synovial cells (Fig. 8b), suggesting leukocyte infiltration is a key drive of molecular 
heterogeneity in RA synovia. 
Next, we asked whether inflammatory cytokines upregulated in leukocyte-rich RA are 
driven by global upregulation within a synovial cell type, or specific upregulation within a 
discrete cell subset defined by scRNA-seq. Whereas TNF was produced at a high level by a 
multiple monocyte, B cell and T cell populations; IL6 expression was restricted to HLAhigh 
sublining fibroblasts (SC-F2) and naive B cells (SC-B1) (Fig. 8c). Similarly, expression of IL1B 
and CXCL13 was restricted to IL1B+ pro-inflammatory monocytes (SC-M1) and Tph/Tfh cells 
(SC-T3), respectively. Surprisingly, we identified CD8 T cells, rather than CD4 T cells, as the 
dominant source of IFNγ in leukocyte-rich synovia.   
We also observed cell subset-specific responses to inflammatory pathways. Toll-like 
receptor signaling pathway was strongly enriched in B cells and monocytes in leukocyte-rich RA 
tissues (Fig. 8a). At the single cell level, we observed that TLR10 was only expressed by HLA+ 
B cells, indicating that TLR10 has a functional role within the B cell lineage37. In contrast, TLR8 
was significantly elevated in all RA monocyte subsets. The hematopoietic cell-specific 
transcription factor IRF8 was expressed in a significant fraction of monocytes and HLA+ B cells 
that cooperatively regulate differentiation of monocytes and activated B cells in RA synovium. 
SLAMF7, a potential therapeutic target for Systemic Lupus Erythematosus (SLE)38, is highly 
expressed by pro-inflammatory monocytes (SC-M1), IFN-activated monocytes (SC-M4), 
plasmablasts (SC-B4) and CD8 T cells. 
DISCUSSION 
Using multi-model, high-dimensional synovial tissue data we defined stromal and immune cell 
populations expanded in RA indicating essential inflammatory pathways. Recognizing the 
considerable variation in clinical parameters for disease duration and activity, treatment types, 
and joint histology scores39,40, we elected to use a molecular parameter, based on percent 
lymphocytes, monocytes of the total cellularity, to classify our samples at the local tissue level. 
We note that differences in leukocyte enrichment of joint replacement samples and biopsy 
samples were best explained by leukocyte infiltration and not by the tissue source 
(Supplemental Fig. 1, Supplemental Fig. 9d-g). Flow cytometry may be a powerful way to 
classify samples that complements histologic assessment. We also observed that the cell 
density from histology samples is correlated with the lymphocytes flow cytometric cell yields, 
which suggested the samples with the most single cell measurements are the samples with the 
best yields and the most inflammation (Supplemental Fig. 19). 
This and previous studies have highlighted stromal fibroblasts as a potential therapeutic 
target in RA41,12. Consistent with previous reports12,23,42, we identified sublining fibroblasts as a 
major producer of pro-inflammatory cytokines, notably IL6, within the leukocyte-rich synovium 
(Fig. 4). Furthermore, a single subset of those fibroblasts expressing MHC II (SC-F2, 
THY1+CD34–HLA-DRhigh) was >15 fold expanded in RA tissues, highlighting it as a possible 
therapeutic target. In addition, MHC II expression supports a role for stromal cells in T cell 
antigen presentation43. We also observed that T cells, B cells, and monocyte proportions track 
with synovial fibroblasts gene expression, suggesting that synovial fibroblasts respond to 
infiltrating lymphocytes in RA synovium (Supplemental Fig. 10). Intriguingly, DNASE1L3, a 
gene whose loss of function is associated with RA44 and systemic lupus erythematosus45 
susceptibility in recent genetic studies, was found to be highly expressed in synovial CD55+ 
lining fibroblasts (SC-F4), which was relatively depleted in human RA. We identified a novel 
fibroblast subset (SC-F3) characterized by high DKK3 (Fig. 4), encoding Dickkopf3, and protein 
upregulated in OA that prevents cartilage degradation in vitro46,47. 
Transcriptional heterogeneity and immunofluorescence images in the synovial monocyte 
compartment indicated that distinct RA-enriched subsets are driven by inflammatory cytokines 
(such as IL-1) and interferons (Fig. 5, Fig. 8). This suggests monocyte may be sensitive to the 
local microenvironment with unique cytokine combinations constituting the inflammatory milieu 
in the RA synovium. These inflammatory phenotypes align with effective RA therapeutic targets, 
for example TNF and the interferon-activated JAK kinases, respectively48,49. The NUPR1+ 
monocytes demonstrated lower proportions in RA tissue and had transcriptomes that were anti-
correlated with the inflammatory phenotypes, suggesting either an anti-inflammatory phenotype, 
supported by high levels of MERTK (Fig. 5)50, or an unrecognized monocyte phenotype specific 
to the normal uninflamed synovium. Alternatively, NUPR1+ markers such as osteoactivin 
(GPNMB) and cathepsin K (CTSK) could indicate a specific subset of osteoclast progenitors 
that control bone remodeling (Fig. 5)51,49,52. Further studies on normal and various disease 
control synovial tissues may clarify the functional role of the NUPR1+ (SC-M2) monocyte 
phenotype. Furthermore, anatomical and spatial studies of the identified monocyte 
populations—particularly focused on lining versus sublining, perivascular and lymphocyte 
aggregate-associated monocytes—will help to elevate our understanding of the functional roles 
for these myeloid cell types. 
Single cell classification of T cell subsets in RA synovium demonstrated CD4+ T cell 
heterogeneity that is consistent with distinction between the homing capacity and effector 
functions of these subsets. Consistent with previous studies, we observed expansion of CD4+ T 
peripheral helper cells20 (SC-T3, CD4+PD-1+ICOS+) within leukocyte-rich RA synovium. We also 
identified distinct CD8 T cell subsets (SC-T4-6) characterized by a distinct granzyme expression 
pattern and high expression of IFN𝛾 and (Fig. 6a). In a protein level validation, we observed 
HLA-DR+ CD8 T cells are preferentially found among CD8+GzmB+GzmK+ (Supplemental Fig. 
16b). We also confirmed that CD8 T cells make IFN𝛾 at a higher frequency than CD4 T cells 
from the same synovial tissue sample (Supplemental Fig. 16c). A larger study may be better 
powered to differentiate the relative expansion of individual subpopulations. 
To our knowledge, this study is the first to report the presence of autoimmune-
associated B cells (SC-B3, ABCs) by transcriptomic sequencing data in leukocyte-rich synovium 
in RA. This B cells population, dependent on T-bet for generation and expressing CD11c, was 
first reported in aging mice; subsequently it was seen to be expanded in autoimmune mice and 
enriched for autoreactive specificities53,54. We observed heterogeneity in this cell subset, with a 
sizable population of CD11c+ B cells detectable in both IgD+ and switched B cell populations by 
mass cytometry. The expression of other markers by ABCs in our transcriptome analysis 
suggests a balance between germinal center (IRF8, AID)55  and plasma cell (SLAMF7) 
differentiation programs within the RA synovium. We observed that multiple B cell subsets 
expressed MHC II, consistent with the potential for B cell antigen presentation in the RA target 
tissue. As previously reported, we also found an expansion of plasmablasts (SC-B4) in 
leukocyte-rich RA synovium. Whether enrichment for this cluster is indirectly targeted by 
rituximab56, 57 may function as a biomarker of response to treatment with B cell depletion needs 
more investigation. We also observe that naive B cells are a dominant IL6 producer. In contrast 
to leukocyte-rich RA, OA synovia contain comparatively few B cells (Fig. 2b), which limited our 
ability to identify RA-associated synovial B cell subsets through case-control comparisons (Fig. 
7g).     
A critical unmet need in RA is identifying therapeutic targets for patients failing to 
respond to DMARDs and biologics39. We observed upregulation of chemokines (CXCL8, 
CXCL9, and CXCL13), cytokines (IFNG and IL1558,59), and surface receptors (PDGFRB and 
SLAMF7) in distinct immune and stromal cell populations, suggesting potential novel targets. 
This study was enabled by important advances in the statistical analysis of single-cell data21,60–63 
alongside rapid improvements in scaling single cell technologies17,64 and our recent work 
optimizing robust methodologies for disaggregation of synovial tissue24. 
We advance strategies to integrate multiple molecular data sets; these approaches 
modulate the effect of technical artifact, frequently confounding single cell technologies65–67, 
while emphasizing biological signals. Our CCA-based integrative strategy clusters high-
dimensional scRNA-seq data using canonical variates that capture variance that are present in 
both the single-cell and bulk RNA-seq data. These shared variances likely represent biological 
trends, and not technical factors that would likely be uncorrelated in these two independent data 
sets. We further confirmed that single-cell cell type clusters that identified by the CCA-based 
strategy are well correlated with the bulk RNA-seq data and also the mass cytometry data on 
typical cluster markers (Supplemental Fig. 11-12). CCA has been successfully employed 
effectively in other contexts to integrate high-dimensional biological data68,67. Penalized CCA69 
and deep CCA70,71 can produce non-linear variates and may prove to be highly effective as we 
confront higher throughput platforms with greater cell-to-cell data. 
The two single cell modalities used in this study, mass cytometry and scRNA-seq, 
complement each other. Single-cell RNA-seq captures expression of thousands of genes72,73, 
but at the cost of sparse data65. A single mass cytometry assay captures hundreds of thousands 
of individual cells, but only measures a limited number (~40)74 of pre-selected markers. But, 
since markers are backed with decades of experimental experience they can be effective at 
defining cellular heterogeneity75. Mass cytometry analysis across all cell populations identified 
that leukocyte-rich patients show high cell abundances of HLA-DR+ fibroblast populations, Tph 
cells, CD11c+CD14+ monocytes, and CD11c+ B cell populations (Supplemental Fig. 6e). To 
make the analysis consistent, we gated mass cytometry cells on the same markers that the 
scRNA-seq was gated. Combining mass cytometry with the extended dimensionality of scRNA-
seq analyses, enables quantification of well-established cell populations, while also enabling 
discovery of rare or novel cell states, such as the CD8 T cell states noted here. We will examine 
whole ungated cellular populations of synovial tissues in the ongoing AMP Phase 2 study using 
the recent development of approaches to capture mRNA and protein expression 
simultaneously76,77. 
Whether cell population expansions and molecular pathways highlighted in this study 
represent RA pathogenesis or a downstream effect of inflammation warrants further 
investigation. The RA/SLE AMP is now engaged in obtaining a large collection of synovial 
biopsy specimens and paired blood samples from 150 RA patients for single cell analyses with 
detailed clinical data, disease activity metrics, and ultrasound score evaluation of synovitis. We 
anticipate that this ongoing larger study will enable us to not only define additional 
subpopulations, but to better define their link to clinical sub-phenotypes. 
It is essential to interrogate the tissue infiltration of diseases other than RA, including 
systemic lupus erythematosus, type I diabetes, psoriasis, multiple sclerosis and other organ 
targeting conditions. Application of multiple single cell technologies together can help to define 
key novel populations, thereby providing new insights about etiology and potential therapies. 
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Fig. 3. High-dimensional transcriptomic scRNA-seq clustering reveals distinct cell type subpopulations. a. Clustering of 5,265 cells from all cell types reveals 18 
distinct cell type subpopulations. b. Distribution of identified cell clusters reveals heterogeneity of individual donors. c. Distinct synovial fibroblast subsets 
including three types of THY1+ sublining fibroblasts (SC-F1, SC-F2, and SC-F3) and CD55+ lining fibroblasts (SC-F4). d. Distinct monocyte subsets including 
two activated cell states of IL1B+ pro-inflammatory (SC-M1) and IFN-activated (SC-M4) monocytes. e. Heterogeneity in synovial T cells: CD4+ subsets: SC-T1, 
SC-T2, SC-T3, and CD8+ subsets: SC-T4, SC-T5, and SC-T6. f. Distinct B cells subsets including HLA+ (SC-B1, SC-B2, and SC-B3) and plasmablasts (SC-
B4). The cluster colors in c-f are consistent with the colors in the clustering of all the cells (a).   
d B cellse 
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Fig. 4. Distinct synovial fibroblasts defined by cytokine activation and MHC II expression. a. scRNA-seq analysis identified three sublining fibroblasts, CD34+
(SC-F1), HLAhigh (SC-F2), and DKK3+ (SC-F3) and one lining subset (SC-F4). Differential analysis on leukocyte-rich RA (n=16) with OA (n=12) by bulk RNA-seq
fibroblast samples defined upregulation/downregulation of cluster marker genes in leukocyte-rich RA. Effect size with 95% confidence intervals are given. b. By 
querying the leukocyte-rich RA (n=16) and OA (n=12) fibroblast bulk RNA-seq samples, scRNA-seq cluster HLA+ (SC-F2) and CD34+ (SC-F1) fibroblasts are 
significantly upregulated (two-tailed Student’s t-test p=2e-6, t-value=6.2, df = 23.91 and p=2e-3, t-value = 3.20, df = 25.41, respectively) in leukocyte-rich RA, 
while lining cells (SC-F4) are enriched (two-tailed Student’s t-test p=5e-7, t-value=-5.31, df =21.97) in OA samples. c. Pathway enrichment analysis indicates the 
potential pathways for each cluster. d-e. Identified clusters and disease status by mass cytometry. f-g. Normalized intensity of distinct protein markers shown in 
tSNE visualization and heatmap. h. Integration of identified mass cytometry clusters with bulk RNA-seq using CCA. First two canonical variates (CV) separated 
genes that upregulated in leukocyte-rich RA from genes that depleted in leukocyte-rich RA. HLAhigh genes are highly associated with THY1+CD34– HLA-DRhigh
by mass cytometry. i. Integration of mass cytometry clusters with scRNA-seq clusters based on the top markers (AUC > 0.7) for each scRNA-seq cluster using 
top 10 canonical variates in the low-dimentional CCA space. We computed the spearman correlation between each pair of scRNA-seq cluster and mass 
cytometry cluster in the CCA space and performed permutation test 104 times. Z-score is calculated based on permutation p-value. We observed HLAhigh
sublining fibroblasts are strongly correlated with THY1+CD34–HLA-DRhigh fibroblasts by mass cytometry.
i































































































































































































































































































































1 2 3 4 5
Normalized intensity












































































































1/16 1/14          16
Fold change
Bulk RNA-seq
OA  leukocyte-rich RA



















1/4    1/2      1       2      4
OA      leukocyte-rich RA













Extracellular matrix structural constituent
Regulation of ossification
Positive regulation of response to wounding
Positive regulation of inflammatory response
Collagen binding
Regulation of sodium ion transport
Antigen processing/presentation of peptide antigen via MHC II




















































































































Fig. 5. Unique activation states define synovial monocytes heterogeneity. a. scRNA-seq analysis identified four subsets: IL1B+ pro-inflammatory monocytes 
(SC-M1), NUPR1+ monocytes (SC-M2) with a mixture of RA and OA cells, C1QA+ (SC-M3), and IFN-activated monocytes (SC-M4). Differential analysis by 
bulk RNA-seq on leukocyte-rich RA samples (n=17) and OA samples (n=13) revealed upregulation/downregulation of cluster marker genes. Effect size with 
95% confidence intervals are given. b. By querying the bulk RNA-seq, we found scRNA-seq cluster IL1B+ pro-inflammatory monocytes (two-tailed Student’s t-
test p=6e-5, t-value=4.56, df =26.33) and IFN-activated monocytes (two-tailed Student’s t-test p=6e-3, t-value=3.28, df =23.68) are upregulated in leukocyte-
rich RA, while SC-M2 is depleted (two-tailed Student’s t-test p=2e-5, t-value=-5.62, df=26.81) in leukocyte-rich RA samples. c. Pathway enrichment analysis 
indicates the potential pathways for each cluster. The standard names for the immunological gene sets from up to bottom are: Genes down-regulated in 
neutrophils versus monocytes (GSE22886); Genes down-regulated in healthy myeloid cells versus SLE myeloid cells (GSE10325); Genes down-regulated in 
control microglia cells versus those 24 h after stimulation with IFNG (GSE1432); Genes down-regulated in unstimulated macrophage cells versus macrophage 
cells stimulated with LPS (GSE14769); Genes up-regulated monocytes treated with LPS versus monocytes treated with control IgG (GSE9988); Genes up-
regulated in monocytes versus myeloid dendritic cells (mDC) (GSE29618); Genes up-regulated in monocytes versus plasmacytoid dendritic cells (pDC) 
(GSE29618). d. Detection of pro-inflammatory cytokines in inflamed synovium by multicolor immunofluorescence. Immunofluorescent staining with antibodies 
CD14 (red), CD16 (white), IL1B (green), and counterstained with DAPI (blue) identified CD14+IL1B+ cells (white arrow). Image was acquired at 200 
magnification. Scale bar is 100 !". e-f. Identified mass cytometry clusters and disease status. g-h. Normalized intensity of distinct protein markers by tSNE
visualization and heatmap. i. Integration of identified mass cytometry clusters with bulk RNA-seq reveals genes that are associated with CD11c+CD38+ and 
CD11c+CCR2+, like IFITM3, CD38, HBEGF, ATF3, and HLA+ genes. j. Integration of mass cytometry clusters and scRNA-seq clusters revealed that 
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Fig. 6. Synovial T cells display heterogeneous subpopulations in RA synovium. a. scRNA-seq analysis identified three CD4+ subsets: CCR7+ (SC-T1), 
Treg (SC-T2), and Tph/Tfh (SC-T3); and three CD8+  subsets: GZMK+ (SC-T4), CTLs (SC-T5), and GZMK+/GZMB+ (SC-T6). Differential expression 
analysis on leukocyte-rich RA (n=18) comparing with OA (n=13) on sorted T cell bulk RNA-seq samples revealed that CXCL13 is the most significantly 
enriched gene in leukocyte-rich RA. b. Disease association of scRNA-seq clusters by aggregating top markers (AUC>0.7) by comparing leukocyte-rich RA 
with OA using bulk RNA-seq. Tph/Tfh cells (SC-T4) are upregulated (two-tailed Student’s t-test p=0.01, t-value=2.73, df =29.00) in leukocyte-rich RA. c. 
Pathway analysis based on immunologic gene set enrichment indicates the potential enriched T cell states pathways. The brief description of the 
standard names from up to bottom are: Genes up-regulated in CD4 high cells from thymus: Treg versus T conv (GSE42021); Genes up-regulated in 
comparison of effector CD8 T cells versus memory CD8 T cells (GOLDRATH); Genes down-regulated in comparison of effector memory T cells versus 
central memory T cells from peripheral blood mononuclear cells (PBMC) (GSE11057); Genes up-regulated in comparison of effective memory CD4 T cells 
versus Th1 cells (GSE3982); Genes up-regulated in comparison of T follicular helper (Tfh) cells versus Th17 cells (GSE11924). d. Detection of 
CD3+CD8+IFN#+ in inflamed synovium by multicolor immunofluorescence. Immunofluorescent staining with antibodies CD8(red), IFN# (white), CD3 
(green), and counterstained with DAPI (blue) identified CD3+CD8+IFN#+ (white arrow). Image was acquired at 200 magnification. Scale bar is 100 !". e-f. 
Identified mass cytometry clusters and disease status. g-h. Distinct patterns of protein markers by tSNE and heatmap that define these clusters. i. 
Integration of identified mass cytometry clusters with bulk RNA-seq using CCA reveals bulk genes that are associated with CD4+ PD-1+ ICOS+ and CD8+ 
PD-1– HLA-DR+ by mass cytometry. j. Integration of mass cytometry clusters with scRNA-seq clusters by taking the average of the top markers (AUC>0.7) 
for each scRNA-seq cluster in the top 10 canonical variates. Z-score based on permutation test reveals that CD4+ PD-1+ ICOS+ and CD8+ PD-1+ HLA-DR+
by mass cytometry are highly associated with Tph/Tfh (SC-T3) by scRNA-seq; CD8+ PD-1– HLA-DR+ T cells by mass cytometry are highly associated with 
CD8+ T cells (SC-T4, SC-T5, and SC-T6). 
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Fig. 7. Synovial B cells display heterogeneous subpopulations in RA synovium. a. scRNA-seq analysis identified naïve B cells (SC-B1), memory B cells (SC-
B2), autoimmune-associated B cells (ABCs) (SC-B3), and plasmablasts (SC-B4). Differential expression analysis by comparing leukocyte-rich RA (n=16) with 
OA (n=7) by bulk RNA-seq B cell samples. b. Pathway enrichment analysis using immunologic gene sets indicates the distinct enriched pathways for each 
scRNA-seq cluster. The standard names for the immunological gene sets from up to bottom are: Genes up-regulated in plasma cells versus memory B cells 
(GSE12366); Genes up-regulated in comparison of B cells versus plasmacytoid dendritic cells (pDC) (GSE29618); Genes up-regulated in B lymphocytes: 
naïve versus plasmablasts (GSE42724); Genes up-regulated in B lymphocytes: human germinal center light zone versus dark zone (GSE38697); Genes up-
regulated in comparison of memory IgM B cells versus plasma cells from bone marrow and blood (GSE22886); Genes up-regulated in comparison of memory 
IGG and IGA B cells versus plasma cells from bone marrow and blood (GSE22886). c. Detection of CD20+Tbet+CD11c+ in inflamed synovium by multicolor 
immunofluorescence. Immunofluorescent staining with antibodies CD20 (red), Tbet (green), CD11c (white), and counterstained with DAPI (blue) identified 
CD20+Tbet+CD11c+ (white arrow). Image was acquired at 200 magnification. Scale bar is 100 !". d-e. Identified mass cytometry clusters and disease status. 
f-g. Distinct expression patterns of protein markers by tSNE and heatmap that define these clusters. h. Integrating mass cytometry clusters with bulk RNA-seq
data using CCA shows that CD38+ CD20– Ig– (plasmablasts) is highly associated with gene expression of plasma cells makers, like XBP1. i. Integration of 
mass cytometry clusters with scRNA-seq clusters suggested that CD38+ CD20– IgM+ and CD38+ CD20– Ig– are significantly associated with plasmablast (SC-
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Fig. 8. Transcriptomic profiling of synovial cells reveal upregulation of inflammatory pathways in RA synovium. a. Pathway enrichment driven by PCA analysis 
and differential expression analysis using bulk RNA-seq identified shared and unique inflammatory response pathways for each cell type. b. Bulk RNA-seq
profiling of genes obtained from the significantly enriched pathways from (a) shows the averaged gene expression from different disease cohorts (OA, 
leukocyte-poor RA, and leukocyte-rich RA) normalized across all cell type samples. c. scRNA-seq profiling resolved that inflammatory cytokines/chemokines, 
interferon responsive, and inflammatory responsive genes were driven by a global upregulation within a synovial cell type or discrete cell states.
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